Evans syndrome
Reading File
Finding Sources
Searching PubMed
Evans syndrome autoimmune hemolytic anemia thrombocytopenia
Reading File
Finding Sources
Reading Article
PMID: 38968944
Reading File
Reading Article
PMID: 40717001
Reading File
Finding Sources
Reading File
Now I have enough information from authoritative sources to give a comprehensive answer. Let me compile it.
Evans Syndrome
Definition
Evans syndrome is a rare autoimmune disorder defined by the simultaneous or sequential occurrence of at least two autoimmune cytopenias:
- Autoimmune hemolytic anemia (AIHA) - almost always warm-type
- Immune thrombocytopenia (ITP)
- Autoimmune neutropenia (in ~25% of cases)
The autoantibodies target red blood cells and platelets (glycoprotein IIb/IIIa is the usual platelet target), leading to peripheral destruction of multiple cell lines. - Henry's Clinical Diagnosis and Management by Laboratory Methods
Epidemiology & Background
- Incidence: ~10-30 times lower than isolated AIHA or ITP individually
- No sex predilection (unlike isolated AIHA, which has a female predominance)
- Half of all cases are secondary (associated with an underlying disorder)
- Historically classified as "idiopathic," but is increasingly recognized as secondary to identifiable immune dysregulation
Associations / Secondary Causes
Evans syndrome should prompt a search for an underlying cause:
| Category | Examples |
|---|---|
| Systemic autoimmune disease | SLE, antiphospholipid antibody syndrome, RA |
| Primary immunodeficiency | Common variable immune deficiency (CVID), Autoimmune Lymphoproliferative Syndrome (ALPS) |
| Lymphoproliferative disorders | CLL, lymphomas |
| Post-transplant | After hematopoietic stem cell transplantation (HSCT) or solid organ transplant |
| Iatrogenic | Immune checkpoint inhibitors (e.g., nivolumab) |
In children and young adults, Evans syndrome strongly suggests ALPS (Autoimmune Lymphoproliferative Syndrome) and this must be actively excluded. - Henry's Clinical Diagnosis and Management; Harrison's 22nd Ed.
In adults, CVID is an important underlying cause to consider.
Pathophysiology
- Warm IgG autoantibodies against RBC antigens (usually Rh-specific) bind to red cells at 37°C
- The Fc portion of the bound IgG is recognized by macrophage Fc receptors - triggering erythrophagocytosis predominantly in the spleen
- Platelet autoantibodies (typically anti-GP IIb/IIIa) mediate platelet destruction similarly
- The result is extravascular hemolysis + peripheral platelet destruction
- Evans syndrome represents profound dysregulation of immune self-tolerance across multiple cell lineages - Harrison's Principles of Internal Medicine, 22nd Ed.
Clinical Features
- Anemia: fatigue, pallor, jaundice, possible splenomegaly - can be abrupt and severe (Hb dropping to as low as 4 g/dL)
- Thrombocytopenia: petechiae, purpura, mucosal/cutaneous bleeding
- Neutropenia (in ~25%): increased susceptibility to bacterial infections
- Disease course: severe, often relapsing - Evans syndrome signals high-risk disease compared to isolated AIHA or ITP
- Complications include: infectious events, thrombotic complications (especially with antiphospholipid antibodies), and sometimes fatal outcomes
Diagnosis
Laboratory Findings
| Test | Expected Finding |
|---|---|
| CBC | Anemia + thrombocytopenia ± neutropenia |
| Peripheral smear | Spherocytes (extravascular hemolysis) |
| Direct Antiglobulin Test (DAT / Coombs) | Positive - cornerstone of AIHA diagnosis |
| Reticulocyte count | Elevated (regenerative anemia), except if marrow also targeted |
| LDH | Elevated |
| Bilirubin (indirect) | Elevated |
| Haptoglobin | Decreased |
Additional Workup (per 2024 Consensus)
- Bone marrow evaluation and CT scan are recommended
- Workup for SLE, antiphospholipid antibodies, ALPS (lymphocyte subsets, soluble Fas ligand), and CVID
- Viral serology (EBV, CMV, HIV, HCV)
Treatment
Treatment is complex and often requires sequential lines of therapy, given the high relapse rate. The first international consensus recommendations for adult Evans syndrome were published in The Lancet Haematology in 2024 (Fattizzo et al., PMID 38968944).
First-Line
- Corticosteroids (prednisone 1 mg/kg/day) - produces remission in at least 50% of patients
- IV immunoglobulins (IVIG) - used adjunctively, especially for acute thrombocytopenia
- Rituximab (anti-CD20) is strongly recommended as first-line for cold-type AIHA; increasingly used with prednisone upfront for warm AIHA as it reduces relapse rates (low dose: 100 mg/week x 4 weeks)
Second-Line
- Rituximab (for warm AIHA and ITP, if not used first-line)
- Splenectomy: removes the major site of hemolysis; response rates similar to rituximab, but carries risk of post-splenectomy sepsis and thrombosis - discouraged in patients with immunodeficiency or severe infections
- Thrombopoietin receptor agonists (TPO-RAs): recommended for chronic ITP component
Third-Line and Beyond
- Fostamatinib (Syk kinase inhibitor, blocks erythrophagocytosis signaling) - recommended as third-line or further
- Immunosuppressants: azathioprine, cyclophosphamide, cyclosporine, mycophenolate
- Sutimlimab (complement C1s inhibitor): for relapsed cold AIHA
- Rituximab + bendamustine: for Evans syndrome secondary to lymphoproliferative disorders
- In severe refractory cases: high-dose cyclophosphamide or alemtuzumab (anti-CD52)
Supportive Care
- EPO: when anemia is accompanied by inadequate reticulocyte output
- Blood transfusion: for life-threatening anemia (ABO-matched but incompatible units may be required - "transfuse incompatible rather than let the patient die")
- Antibiotic and thrombotic prophylaxis where indicated
- Harrison's Principles of Internal Medicine, 22nd Ed.; Lancet Haematol 2024
Prognosis
Evans syndrome carries a worse long-term prognosis than isolated AIHA or ITP:
- High relapse rate
- Risk of fatal infectious and thrombotic complications
- Predictors of poor outcome: severe anemia (Hb <6 g/dL), acute renal failure, certain antibody characteristics, concurrent infection
The 2025 review by Jiang & Kuter (PMID 40717001) notes that several novel therapies targeting FcRn (neonatal Fc receptor) and other pathways are under active investigation for both AIHA and ITP components, which may offer improved outcomes for Evans syndrome patients.
Key takeaways:
- Evans syndrome = AIHA + ITP ± autoimmune neutropenia
- Always look for a secondary cause - especially ALPS in children/young adults, CVID in adults
- Positive DAT is the cornerstone lab finding
- Treatment escalates through steroids → rituximab ± IVIG → splenectomy/TPO-RAs → fostamatinib/immunosuppressants
- Prognosis is worse than either cytopenia alone - close follow-up is mandatory
This is a shared conversation. Sign in to Orris to start your own chat.